The complexity of cardiovascular diseases may require combination therapies, such as multiple PDE inhibitors or simultaneously activating AC and GC and blocking PDEs, to fine-tune cyclic nucleotide levels in specific subcellular compartments, providing more effective therapies with favorable risk-benefit profiles (7, 9). Here, ALDH7A1 is linked to cardiovascular disorder.